% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lakes:308548,
      author       = {J. Lakes and M. Boschheidgen and G. Antoch and M. K. Klett
                      and A. Karger and R. Roth and S. Redler and M. G. Pai and D.
                      Wieczorek and B. Jäger and T. N. Fehm and G. Niegisch and
                      T. T. Rau and P. Albers$^*$},
      title        = {{G}enetic {T}esting and {I}maging in {M}en with {F}amilial
                      {H}istory or {G}enetic {P}redisposition of {P}rostate
                      {C}ancer-{I}ntroducing the {P}rospective '{P}ro{F}am-{R}isk'
                      {S}tudy.},
      journal      = {European urology open science},
      volume       = {84},
      issn         = {2666-1691},
      address      = {[Amsterdam]},
      publisher    = {Elsevier ScienceDirect},
      reportid     = {DKFZ-2026-00174},
      pages        = {13 - 21},
      year         = {2026},
      note         = {#LA:C130#},
      abstract     = {Familial and genetic factors influence prostate cancer
                      (PCa) risk, necessitating personalized prevention
                      strategies. This study aims to establish and validate a
                      prevention clinic (ProFam-Risk) for men with a familial or
                      genetic risk of PCa, focusing on genetic testing,
                      multiparametric magnetic resonance imaging (mpMRI), and
                      psychosocial assessment. ProFam-Risk is a prospective
                      registry and outpatient clinic at the University Hospital
                      Düsseldorf, recruiting participants into three groups:
                      healthy men with a familial risk (having two or more
                      affected relatives or early-onset PCa), men with pathogenic
                      germline variants (eg, BRCA1/2), and PCa-affected men
                      meeting familial/genetic criteria. Participants undergo
                      prostate-specific antigen testing, mpMRI, genetic analysis,
                      psychosocial assessment, and receive risk-adapted
                      recommendations for cancer prevention. Outcome measures
                      include prevalence of pathogenic variants, PCa detection
                      rates, and the impact of genetic counseling and mpMRI on
                      clinical decision-making.},
      keywords     = {Genetic risk (Other) / Multiparametric magnetic resonance
                      imaging (Other) / Pathogenic germline variants (Other) /
                      Personalized screening (Other) / Prostate cancer (Other)},
      cin          = {C130},
      ddc          = {610},
      cid          = {I:(DE-He78)C130-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41561489},
      pmc          = {pmc:PMC12814690},
      doi          = {10.1016/j.euros.2025.12.018},
      url          = {https://inrepo02.dkfz.de/record/308548},
}